True North Labs

Author: labstruenorth@gmail.com

  • New Clinical Trial Explores Advanced PET Imaging to Better Detect Lung Sarcoidosis

    New Clinical Trial Explores Advanced PET Imaging to Better Detect Lung Sarcoidosis

    A new clinical trial is examining how several positron emission tomography (PET) tracers, including the widely used [18F]FDG, might help clinicians better visualize active granulomas in patients with pulmonary sarcoidosis. Sarcoidosis is an inflammatory condition that can cause small clusters of immune cells, known as granulomas, to form in the lungs, and accurately identifying active disease has traditionally been a challenge for physicians.

    The study is evaluating tracers that are already approved and in routine clinical use for detecting other types of inflammation or certain tumors. Because the molecular pathways involved in these conditions share some similarities with the processes seen in sarcoidosis, researchers are hopeful that these existing imaging agents could be repurposed to offer a clearer picture of disease activity in the lungs.

    One of the promising aspects of this approach is that it builds on tracers with established safety profiles, rather than requiring entirely new compounds to go through the full development pipeline. If successful, this could mean a faster path toward improved diagnostic tools, giving doctors more precise ways to track how active a patient’s sarcoidosis is over time and potentially guide treatment decisions with greater confidence.

    Better imaging techniques could also reduce reliance on more invasive diagnostic procedures, offering patients a more comfortable path to accurate assessment. As the trial progresses, researchers will be looking at how well each tracer highlights areas of active inflammation, which could eventually help clinicians distinguish between active and inactive disease stages more reliably.

    This kind of research reflects the broader value of exploring new applications for existing medical tools, potentially accelerating the timeline for bringing improved diagnostic options to patients living with pulmonary sarcoidosis. As always, this article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis

  • New Clinical Trial Explores Combination Therapy for Hard-to-Treat Lung and Neuroendocrine Cancers

    New Clinical Trial Explores Combination Therapy for Hard-to-Treat Lung and Neuroendocrine Cancers

    Researchers have launched a phase II clinical trial examining a promising combination approach for small cell lung cancer and other high-grade neuroendocrine carcinomas—cancers that are notoriously difficult to treat and in need of new therapeutic options. The study pairs niraparib, a PARP inhibitor, with dostarlimab, a monoclonal antibody immunotherapy, to see whether combining these two distinct treatment strategies can offer better outcomes for patients.

    Niraparib works by blocking PARP, an enzyme that cancer cells rely on to repair damaged DNA. By inhibiting this repair process, the therapy aims to make it harder for cancer cells to survive, potentially causing them to die off more effectively. This targeted approach has already shown value in other cancer types, and researchers are now exploring its potential in the challenging landscape of neuroendocrine carcinomas.

    Dostarlimab, meanwhile, is designed to help the immune system recognize and attack cancer cells more effectively. As a monoclonal antibody therapy, it may also interfere with tumor cells’ ability to grow and spread, offering a complementary mechanism to the DNA-repair-blocking action of niraparib. The hope is that using these two approaches together could provide a more powerful one-two punch than either treatment alone.

    What makes this trial particularly encouraging is its focus on a group of cancers—small cell lung cancer and high-grade neuroendocrine carcinomas—that have historically had limited treatment options and challenging prognoses. Phase II trials like this one are a critical step in the research pipeline, helping scientists understand whether a combination therapy is both safe and effective enough to warrant larger-scale studies. Progress in this area could eventually translate into more choices and better outcomes for patients facing these difficult diagnoses.

    As with all clinical research, it will take time to gather and analyze results, but the initiation of this trial reflects the ongoing commitment of the oncology research community to innovate and improve care for patients with aggressive, hard-to-treat cancers. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

  • FDA Advisory Committee Expresses Support for Popular Wellness Peptides

    FDA Advisory Committee Expresses Support for Popular Wellness Peptides

    In a notable development for the peptide community, an FDA advisory committee has voted to back a group of popular wellness peptides, according to a recent report. Advisory committees play an important role in the FDA’s decision-making process, offering independent expert review of scientific and safety data before the agency finalizes its regulatory stance.

    While FDA staff reportedly raised some questions during the review process, the committee’s supportive vote is an encouraging signal for consumers and practitioners who have come to value these peptides as part of wellness routines. Advisory committee recommendations, while not binding, often carry significant weight in shaping the FDA’s ultimate decisions and can influence future access and availability.

    This kind of formal review process is a positive sign of the regulatory system working as intended, bringing together expert scientific judgement to carefully weigh the benefits and considerations associated with these compounds. For the wellness peptide space, this kind of engagement from regulators and independent experts helps build a stronger foundation for continued availability and responsible use going forward.

    Though specific details of the committee’s discussions and the particular peptides involved continue to develop, the overall outcome represents a step toward clearer regulatory pathways. Continued dialogue between regulators, scientific experts, and the wellness community is an encouraging part of ensuring that beneficial compounds can reach those who may find value in them.

    As always, we’ll continue to follow how this regulatory process unfolds and what it may mean for access to wellness peptides moving forward. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Updated: FDA adcomm backs popular wellness peptides, despite staff concerns – Endpoints News

  • The Growing Landscape of FDA-Approved Peptide Therapies for Weight Management

    The Growing Landscape of FDA-Approved Peptide Therapies for Weight Management

    Peptide-based therapies have become one of the most talked-about developments in modern medicine, particularly in the area of weight management. Over the past several years, the U.S. Food and Drug Administration has approved multiple peptide-based medications that mimic naturally occurring hormones involved in appetite regulation and metabolism. This steady stream of approvals reflects growing confidence from regulators and clinicians in the safety and efficacy data supporting these treatments.

    The success of GLP-1 receptor agonist peptides marked a turning point for the field, demonstrating that carefully designed peptide molecules could produce meaningful, measurable results for people struggling with weight-related health challenges. These approvals didn’t happen overnight — they came after years of clinical trials, safety monitoring, and rigorous review processes designed to ensure that patients have access to treatments that are both effective and well-understood.

    What makes this ongoing progress particularly encouraging is the ripple effect it has had across the broader peptide research community. Pharmaceutical companies and academic researchers alike have been energized to explore how other peptide compounds might be refined, combined, or improved to address weight management from multiple angles — whether through appetite suppression, improved insulin sensitivity, or enhanced metabolic efficiency. This has created a more robust pipeline of innovation than existed just a few years ago.

    For patients, the expansion of FDA-approved options means more choices discussed with healthcare providers, more competition that can help drive improvements in formulation and delivery, and a clearer regulatory pathway that distinguishes well-studied medications from unregulated or unapproved products. As the science matures, continued transparency from regulators about safety data and approval standards remains a cornerstone of building public trust in this emerging class of treatments.

    Looking ahead, the trajectory suggests continued interest from both industry and regulators in refining peptide-based approaches to weight management, with an emphasis on long-term safety data and patient outcomes. This is encouraging news for anyone following the field, as it signals a maturing, evidence-based approach to an important area of public health.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider for guidance on any treatment.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: fda approved peptide drugs for weight loss 2026 – www.polskieradio.pl

  • FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management

    FDA-Approved Peptide Therapies Continue to Expand Options for Weight Management

    Peptide-based medications have become one of the most notable success stories in modern metabolic medicine, with the U.S. Food and Drug Administration approving multiple peptide therapies specifically for weight management in recent years. These approvals mark a significant milestone, giving patients and healthcare providers additional FDA-sanctioned options to address obesity and related health concerns.

    Peptides work by mimicking naturally occurring hormones in the body that regulate appetite, digestion, and blood sugar levels. Several of these compounds, originally developed to help manage type 2 diabetes, have demonstrated meaningful results in supporting weight loss when used alongside diet and exercise. Their FDA approval reflects a rigorous review process that evaluated safety and efficacy data from extensive clinical trials involving thousands of participants.

    What makes this area of peptide research particularly encouraging is the growing body of evidence supporting sustained, clinically meaningful outcomes. Patients using FDA-approved peptide therapies in clinical settings have often reported improvements not just in body weight, but in related markers such as blood pressure and blood sugar control. This holistic benefit profile has helped position peptide medications as an important option within a comprehensive approach to weight management.

    The regulatory green light also signals increased confidence from scientific and medical communities in the broader potential of peptide-based treatments. As research continues, scientists are exploring additional peptide formulations and delivery methods that could further improve accessibility, convenience, and outcomes for patients seeking support in their weight management journey. The pipeline of peptide research remains active, with ongoing studies examining long-term benefits and potential applications beyond weight loss alone.

    For individuals interested in these therapies, consulting with a qualified healthcare provider remains the best path to understanding whether an FDA-approved peptide treatment might be appropriate for their individual health goals. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: fda approved peptides for weight loss – polskieradio.pl

  • New Phase 3 Trial Launches to Explore Rina-S for Ovarian Cancer Maintenance Therapy

    New Phase 3 Trial Launches to Explore Rina-S for Ovarian Cancer Maintenance Therapy

    A new Phase 3 clinical trial has launched to investigate Rina-S, a peptide-based therapeutic, as a potential maintenance treatment for patients with ovarian cancer, including primary peritoneal and fallopian tube cancers. The study will compare Rina-S—used either on its own or in combination with standard of care—to standard maintenance therapy alone following first-line platinum-based chemotherapy.

    The trial is designed to enroll up to approximately 602 participants at sites around the world, reflecting the scale of international collaboration going into refining treatment options for ovarian cancer patients. Maintenance therapy after initial chemotherapy is a critical phase of care, aimed at helping keep cancer from progressing once the first round of treatment has done its work. Research like this is important because it continues to expand the toolkit oncologists may eventually have available for this stage of care.

    Participants in the study can expect to be involved for an average of about four years, including roughly 16 months of active treatment and an extended follow-up period of around 29 months. This long-term design allows researchers to carefully monitor both the safety and effectiveness of the treatment over time, with regular clinic visits that include blood draws, imaging, and other standard monitoring procedures every three-week cycle.

    Importantly, the study is structured to allow participants to continue receiving treatment as long as their cancer remains stable or improves and no significant safety concerns arise. This kind of adaptive, patient-centered trial design reflects a broader trend in oncology research toward giving patients continued access to potentially beneficial therapies for as long as they are helping.

    Trials like this one represent meaningful progress in the search for better maintenance options following chemotherapy, a stage of treatment where effective, well-tolerated therapies can make a real difference in patients’ lives. As the study progresses, it will add to the growing body of research exploring how peptide-based treatments may complement or enhance existing cancer care standards. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer

  • New Phase II Trial Explores Triple Combination Therapy for Richter Transformation

    New Phase II Trial Explores Triple Combination Therapy for Richter Transformation

    A new phase II clinical trial is underway to investigate whether a combination of three distinct cancer-fighting agents—acalabrutinib, venetoclax, and durvalumab—can improve outcomes for patients facing Richter transformation, a rare and historically difficult-to-treat condition in which chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) evolves into a fast-growing lymphoma.

    The trial brings together three different mechanisms of action in hopes that their combined effect may offer more robust results than any single approach alone. Acalabrutinib works by blocking enzymes that cancer cells need to grow. Venetoclax, a BCL-2 inhibitor, targets a protein that helps cancer cells survive, effectively removing one of their key defenses. Durvalumab, an immunotherapy drug, takes a different route entirely by helping the body’s own immune system recognize and attack cancer cells while also disrupting the tumor’s ability to spread.

    This multi-pronged strategy reflects a broader and encouraging trend in oncology research: combining targeted therapies with immunotherapy to tackle cancers that have been historically resistant to single-agent treatments. Richter transformation has long posed a significant challenge for clinicians because of its aggressive nature and historically limited treatment options, so any research aimed at expanding the therapeutic toolkit is a welcome development for patients and families affected by this condition.

    Phase II trials like this one are an important step in the broader drug development pipeline. They build on earlier safety data from phase I studies and begin to assess how effectively a treatment works in a larger patient population, while continuing to monitor safety closely. Should this trial yield promising results, it could pave the way for larger studies and, potentially, new treatment standards for patients with this rare condition.

    While it will take time for full results to emerge, the initiation of this trial represents meaningful progress in the search for better therapies for rare and aggressive blood cancers. It also underscores how researchers continue to explore creative combinations of existing approved therapies to address unmet medical needs. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

  • New Clinical Trial Explores RYZ101 as Next-Step Therapy for Advanced Neuroendocrine Tumors

    A new clinical trial is underway to evaluate RYZ101, an investigational radiopharmaceutical peptide therapy, for patients living with inoperable, advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that express somatostatin receptors (SSTR+). This is a meaningful development for a patient population that often faces limited treatment choices once their disease progresses after initial therapy.

    The study specifically targets patients whose tumors have continued to grow despite prior treatment with Lutetium-177 labelled somatostatin analogue (177Lu-SSA) therapies, such as 177Lu-DOTATATE or 177Lu-DOTATOC. These therapies represent a standard approach for SSTR+ GEP-NETs, but when the disease progresses afterward, oncologists and patients currently have fewer well-established next steps. A trial exploring a new option in this exact clinical scenario addresses a genuine unmet need.

    The trial is structured in two parts. Part 1 is designed to establish the safety profile, pharmacokinetics, and the recommended Phase 3 dose of RYZ101. Part 2 will then compare RYZ101 directly against investigator-selected standard of care therapy, looking at safety, efficacy, and pharmacokinetics. This structured, stepwise approach reflects careful, methodical clinical research practices aimed at generating robust data before any potential wider use.

    RYZ101 belongs to a broader category of targeted radiopharmaceutical peptides that are designed to home in on somatostatin receptors expressed by neuroendocrine tumor cells, delivering therapeutic radiation more precisely to cancerous tissue. This class of therapy has already shown promise in the field of neuroendocrine tumor treatment, and continued research into next-generation or sequential options could expand the toolkit available to clinicians treating this challenging cancer type.

    For patients and families navigating a GEP-NET diagnosis, the existence of trials like this one is an encouraging sign that research continues to advance even for those who have already gone through prior rounds of treatment. As with any investigational therapy, results from Part 1 and Part 2 will need to be fully analyzed before conclusions about safety and effectiveness can be drawn. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

  • FDA Unveils Faster 50-Day Review Pathway for Novel Drugs, Including Peptide Therapeutics

    FDA Unveils Faster 50-Day Review Pathway for Novel Drugs, Including Peptide Therapeutics

    The U.S. Food and Drug Administration has announced a new accelerated review pathway aimed at shortening the time it takes to bring certain new molecular entities (NMEs) to market. Under the updated framework, qualifying drug candidates could see a dramatically compressed review timeline of around 50 days, a significant shift from traditional review periods that often stretch much longer.

    For the peptide therapeutics field, this development is particularly encouraging. Many peptide-based drugs are classified as NMEs due to their novel mechanisms of action and unique molecular structures. A faster regulatory pathway means that promising peptide candidates currently in the pipeline, from metabolic health treatments to targeted therapies, could potentially reach patients sooner than under previous timelines.

    Speeding up review processes without compromising safety standards has long been a goal for both regulators and drug developers. This change suggests the FDA is refining its internal processes to better handle the growing wave of innovative biologics and peptide-based submissions, which have become an increasingly important category of modern medicine in recent years.

    Industry observers note that a more efficient approval process could also encourage greater investment in peptide research and development, as companies may feel more confident allocating resources toward novel candidates knowing there is a clearer, faster route to market for qualifying therapies. This could ultimately translate into a more robust pipeline of peptide-based treatments addressing unmet medical needs.

    While the full details and eligibility criteria for this new pathway continue to emerge, the move represents a positive step toward modernizing drug development timelines in the United States. Patients, researchers, and biotech companies alike stand to benefit from a regulatory environment that can keep pace with scientific innovation.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA’s 50-Day NME Approval Changes Drug Development Rules – PharmTech.com

  • FDA Advisory Panel Recommends Expanded Access to Six Popular Peptides

    In a development that could reshape availability for several popular peptides, an FDA advisory panel has recommended expanding access to six compounds that have drawn significant interest from both patients and practitioners. The panel’s recommendation signals a potentially more favorable regulatory environment for these peptides going forward.

    While specific details about which six peptides are included continue to emerge, the panel’s stance reflects growing recognition within regulatory circles of the therapeutic potential these compounds may offer. Advisory panels play a crucial role in shaping FDA policy, and their recommendations often pave the way for formal rule changes that can expand patient access through legitimate channels like compounding pharmacies.

    This kind of regulatory movement is particularly meaningful for the peptide community, as it suggests a thoughtful, evidence-based approach to balancing safety oversight with accessibility. When advisory panels recommend expanded access, it typically reflects a review of available data suggesting these compounds have a reasonable safety profile and legitimate therapeutic applications worth preserving for patients who may benefit from them.

    For those who follow the peptide space closely, this represents an encouraging signal that regulators are willing to engage constructively with emerging compounds rather than defaulting to restriction. Expanded access through proper regulatory channels also means better quality control and oversight, which benefits everyone from prescribing physicians to end users who want confidence in the products they’re accessing.

    As this recommendation moves through the FDA’s formal review process, the peptide community will be watching closely to see how it translates into concrete policy changes. True North Labs will continue monitoring this story and provide updates as more details about the specific peptides and implementation timeline become available.

    This article is for informational purposes only and is not medical advice. Please consult a qualified healthcare provider before considering any peptide therapy.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: FDA Panel Wants to Expand Access for These 6 Peptides – U.S. News & World Report